Cryptococcus neoformans and cryptococcosis

Journal of Infection

Volumn 41, Issue 1, 2000, Pages 12-17

  Harrison, T S ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; BENZIMIDAZOLE; CYCLOSPORIN; FLUCONAZOLE; FLUCYTOSINE; L 685818; PENTAMIDINE; PNEUMOCANDIN DERIVATIVE; PYRROLE DERIVATIVE; SORDARIN; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE TRANSMISSION; DRUG RESEARCH; ECOLOGY; FUNGAL GENETICS; FUNGUS GROWTH; GENETIC TRANSFORMATION; HIGH RISK PATIENT; HOST RESISTANCE; IMMUNE RESPONSE; LIFE CYCLE; MOLECULAR BIOLOGY; NONHUMAN; PRIMARY PREVENTION; RISK FACTOR; SITE DIRECTED MUTAGENESIS; TEMPERATURE; VIRULENCE;

EID: 0033845312     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2000.0695     Document Type: Article

References (75)

1. Opportunistic infections and diseases
2. Predictors of outcome in Cryptococcus neoformans var. gattii meningitis
3. Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City
4. Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: Evidence for both local genetic differences and a global clonal population structure
5. Random amplified polymorphic DNA analysis of clinically and environmentally isolated Cryptococcus neoformans in Nagasaki
6. Concordance of clinical and environmental isolates of Cryptococcus neoformans var. gattii by random amplification of polymorphic DNA analysis and PCR fingerprinting
7. Cryptococcosis: Population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons
8. Natural habitat of Cryptococcus neoformans var. neoformans in decaying wood forming hollows in living trees
9. Cryptococcus neoformans var. gattii - Evidence for a natural habitat related to decaying wood in a pottery tree hollow
10. Phylogenetic relationships of Cryptococcus neoformans and some related basidiomycetous yeasts determined from partial large subunit rRNA sequences
11. Dimorphism and haploid fruiting in Cryptococcus neoformans: Association with the alpha-mating type
12. Is Cryptococcus neoformans evolving into an asexual organism?
13. Cryptococcal meningitis after unusual exposure to birds
14. Epidemiological evidence for dormant Cryptococcus neoformans infection
15. Cryptococcus neoformans: Virulence and host defences
16. The second capsule gene of Cryptococcus neoformans, CAP64, is essential for virulence
17. Isolation of the third capsule-associated gene, CAP60, required for virulence in Cryptococcus neoformans
18. Isolation, characterization, and localization of a capsule-associated gene, CAP10, of Cryptococcus neoformans
19. A unique alpha-1,3 mannosyltransferase of the pathogenic fungus Cryptococcus neoformans
20. Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans
21. Cryptococcus neoformans melanin and virulence: Mechanism of action
22. Melanin, melanin ghosts, and melanin composition in Cryptococcus neoformans
23. Catecholamine oxidative products, but not melanin, are produced by Cryptococcus neoformans during neuropathogenesis in mice
24. Laccase protects Cryptococcus neoformans from antifungal activity of alveolar macrophages
25. Calcineurin is required for virulence of Cryptococcus neoformans
26. Signal transduction pathways regulating differentiation and pathogenicity of Cryptococcus neoformans
27. The G protein beta subunit GPB1 is required for mating and haploid fruiting in Cryptococcus neoformans
28. The Cryptococcus neoformans STE12alpha gene: A putative Saccharomyces cerevisiae STE12 homologue that is mating type specific
29. Cryptococcus neoformans STE12a regulates virulence but is not essential for mating
30. The STEalpha homolog is required for haploid filamentation but largely dispensible for mating and virulence in Cryptococcus neoformans
31. Targeted gene replacement demonstrates that myristoyl-CoA: Protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans
32. Urease as a virulence factor in experimental cryptococcosis
33. Oxidative killing of Cryptococcus neoformans by human neutrophils. Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates
34. Phospholipase activity in Cryptococcus neoformans: A new virulence factor?
35. The isocitrate lyase gene of Cryptococcus neoformans is expressed during infection
36. Cryptococcus neoformans differential gene expression detected in vitro and in vivo with green fluorescent protein
37. Unique features of elongation factor 3 (EF-3) from Cryptococcus neoformans
38. Cryptococcus neoformans manA gene, encoding for phosphomannose isomerase is essential for virulence in vivo
39. Antibody immunity and invasive fungal infections
40. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice
41. Ig heavy chain complex-linked genes influence the immune response in a murine cryptococcal infection
42. Macrophage-Cryptococcus interactions
43. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody resposiveness to cryptococcal polysaccharide
44. Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages
45. Cryptococcus neoformans survive and replicate in human microglia
46. Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation
47. Mechanisms of macrophage recruitment into infected lungs
48. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice
49. A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans
50. Cytokine treatment of central nervous system infection: Efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis
51. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans
52. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production
53. Combined effects of IL-12 and IL-18 on the clinical course and local cytokine production in murine pulmonary infection with Cryptococcus neoformans
54. Role of IL-12 in peripheral blood mononuclear cell responses to fungi in persons with and without HIV infection
55. Early induction of interleukin-12 by monocytes exposed to Cryptococcus neoformans mannoproteins
56. Priming with IFN-gamma restores deficient IL-12 production by peripheral blood mononuclear cells from HIV-seropositive donors
57. CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection
58. Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans
59. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy
60. Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses
61. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection
62. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model
63. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine
64. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies
65. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
66. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa
67. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro
68. In vitro susceptibility of the opportunistic fungus Cryptococcus neoformans to anthelmintic benzimidazoles
69. Structure-in vitro activity relationships of pentamidine analogues and dication-substituted bis-benzimidazoles as new antifungal agents
70. Sordarins: A new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts
71. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein
72. Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis
73. Conditional lethality of the diprotic weak bases chloroquine and quinacrine against Cryptococcus neoformans
74. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis